News Nicox plans filings for glaucoma after phase 3 win Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.
News Viking felled by dropout rates in oral obesity drug trial Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?
News Pfizer suffers another hit to its GBT sickle cell portfolio Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.
News Vedanta's microbiome therapy for IBD disappoints Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.
News More good news in Sjogren's as RemeGen trial delivers A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.
News Padcev/Keytruda extends survival in early bladder cancer Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.
Digital Sponsored AI-enabled pharmacovigilance, with Updesh Dosanjh Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.